Pomerantz Law Firm Probes Allegations of Securities Fraud at Capricor Therapeutics

Pomerantz Law Firm Investigates Claims Against Capricor Therapeutics

In a recent announcement, the Pomerantz Law Firm is actively investigating potential claims from investors associated with Capricor Therapeutics, Inc. (NASDAQ: CAPR). The firm is reaching out to investors, urging them to contact attorney Danielle Peyton for more information.

The core of the investigation revolves around allegations that Capricor and its executive team may have engaged in practices that could amount to securities fraud or other illicit activities impacting the company's share price. Given the recent developments concerning the company's drug, deramiocel, a cell therapy aimed at treating Duchenne muscular dystrophy (DMD) cardiomyopathy, these allegations have raised significant concern among investors.

On May 5, 2025, Capricor revealed to the public that it had completed a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) as part of its Biologics License Application (BLA) for deramiocel. The announcement created a ripple effect in the market, ultimately resulting in a steep drop of 29.13% in the company's stock value the following day.

Fast forward to June 20, 2025, and further negative news emerged. The publication STAT reported that the new head of the FDA unit handling the case had cancelled the anticipated advisory committee meeting for deramiocel. The report cited uncertainties regarding the drug's safety and efficacy as the reasons behind this significant decision. Following this revelation, Capricor’s stock plummeted again, this time by 30.82%.

As such incidents unfolded, Pomerantz LLP’s investigation gained momentum, shedding light on how such developments could have led to damages for investors. With a long-standing reputation in corporate and securities litigation, Pomerantz LLP aims to uncover whether the company’s actions constituted violations that adversely impacted investors' financial interests.

Founded by the late Abraham L. Pomerantz, renowned for pioneering securities class actions, the firm has helped secure numerous recoveries for victims of corporate misconduct over its 85-year history. This inquiry into Capricor’s practices fits within its tradition of safeguarding the rights of investors.

The investigation will analyze whether the company's leadership misled investors about the prospects of deramiocel, particularly regarding its approval status with the FDA. Investors who wish to join the ensuing class action are encouraged to reach out to Pomerantz for guidance.

For inquiries, any involved parties can connect with Danielle Peyton by emailing [email protected] or via phone at 646-581-9980, extension 7980.

In light of these developments, it's crucial for investors in Capricor to stay informed and vigilant. This situation serves as a reminder of the volatility in the biopharmaceutical sector and the dire need for corporate transparency. Potential investors should carefully consider the implications of Capricor's current standings and the unfolding legal circumstances before making future investments.

This case illustrates the continuing challenges faced within the biopharmaceutical landscape, especially regarding regulatory interactions with the FDA. With prospects of pending litigation and investor claims, Capricor Therapeutics will likely remain in the spotlight, fueling discussions about corporate governance and ethical business practices. Investors and the public alike will be watching closely as this investigation progresses.